Are camels the secret to fighting antibiotic resistance? 

Antimicrobial resistance poses a growing global health crisis, with few new antibiotics in development. According to the Global Research on Antimicrobial Resistance Project, bacterial antimicrobial resistance is projected to cause 39 million deaths between 2025 and 2050, equating to three deaths every minute.


Image by Freepik

To tackle this, researchers at Sultan Qaboos University, Oman, have identified three novel antimicrobial peptides (AMPs) from dromedary camels that effectively target multidrug-resistant bacteria, offering potential alternatives to conventional drugs.

Published in Frontiers in Immunology, the researchers used a combination of computer-based bioinformatics predictions and laboratory experiments to test the peptides. Their experiments included colony-forming assays, membrane permeability tests, and electron microscopy on dangerous bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Escherichia coli.

Two peptides, CdPG-3 and CdCATH, demonstrated strong antibacterial activity against both Gram-positive and Gram-negative bacteria. They work by damaging bacterial cell membranes, which causes the cells to leak and die. Importantly, at lower concentrations these peptides did not significantly harm camel or human red blood cells, suggesting they may be relatively safe.

Camels’ robust innate immunity, including these cathelicidin-like AMPs, helps explain why camels are often more resistant to infections that affect other livestock. "This lays the foundation for exploring camel AMPs as therapeutics against resistant pathogens," noted the authors. 

Unlike traditional antibiotics prone to resistance via target mutations, AMPs disrupt bacterial membranes broadly, reducing adaptation risks. The peptides showed low haemolytic activity in relevant species, supporting safety for further development. 

Future research will optimise these AMPs for clinical use, leveraging Oman's camel resources.

DOI: 10.3389/fimmu.2026.1745714